Revelation Biosciences, Inc.
REVB
$2.72
$0.145.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.52% | 7.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.48% | 19.45% | |||
| Operating Income | -17.48% | -19.45% | |||
| Income Before Tax | -19.18% | -18.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.18% | -18.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.18% | -18.86% | |||
| EBIT | -17.48% | -19.45% | |||
| EBITDA | -17.54% | -19.53% | |||
| EPS Basic | -10.64% | 57.60% | |||
| Normalized Basic EPS | 51.93% | 57.60% | |||
| EPS Diluted | -10.64% | 57.60% | |||
| Normalized Diluted EPS | 51.93% | 57.60% | |||
| Average Basic Shares Outstanding | 147.90% | 180.35% | |||
| Average Diluted Shares Outstanding | 147.90% | 180.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||